In its first year, the industry's precompetitive experiment TransCelerate BioPharma Inc. has hit key milestones in all five of its initial projects aimed at improving the speed and quality of clinical trials. The biopharma consortium also has increased its membership to 18 companies from 10, and could announce its next set of projects this year.

TransCelerate was founded last year after a group of pharma R&D heads concluded that precompetitive collaboration was best way to solve clinical trial bottlenecks. The hope was that the resulting efficiencies would speed up drug development and lower costs for all members.